Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and Connected Persons regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Transaction Price: $52.0208 per ADS.
- Transaction Date: April 11, 2014.
- Transaction Type: Re-investment of dividends paid on April 10, 2014.
Material Changes
The filing details increases in share interests for specific individuals following dividend re-investment. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transactions were executed on April 11, 2014, at a price of $52.0208 per ADS.
- Dr. M M Slaoui increased holdings by 1,788.686 ADSs; his connected person, Dr. K Slaoui, increased holdings by 20.762 ADSs.
- Other directors with increased holdings include Mrs. D P Connelly (895.847 ADSs), Mr. J Ford (34.235 ADSs), Mr. W C Louv (301.078 ADSs), and Mr. D E Troy (825.851 ADSs).
- The Company was advised of these transactions on April 16, 2014.